Comparing Health Outcomes and Costs of General Vaccination with Pneumococcal Conjugate Vaccines in Sweden: A Markov Model

Asa By, Patrik Sobocki, Arne Forsgren, Sven-Arne Silfverdal

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Two new pneumococcal conjugate vaccines were licensed to immunize infants and young children against pneumococcal disease. Objectives: The objective of this study was to estimate the expected health benefits, costs, and incremental cost-effectiveness of routine vaccination with the 10-valent pneumococcal nontypeable hemophilus influenza protein-D conjugate vaccine (PHiD-CV) compared with the 13-valent pneumococcal conjugate vaccine (PCV13) in Sweden. Methods: A Markov cohort model was used to estimate the effect of vaccination at vaccine steady state, taking a societal perspective and using a 2+1 vaccination schedule. Price parity was assumed between the vaccines. Outcomes were measured by reduction in disease burden, costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio. Results: The results predicted that PCV13 would prevent 3 additional cases of invasive pneumococcal disease and 34 additional cases of pneumonia, whereas PHiD-CV would avoid 3 additional cases of mastoiditis, 1010 tube insertions, and 10,420 cases of ambulatory acute otitis media compared with PCV13. By combining morbidity and mortality benefits of all clinical outcomes, PHiD-CV would generate 45.3 additional QALYs compared with PCV13 and generate savings of an estimated 62 million Swedish kronors. Conclusion: The present study predicted lower costs and better health outcome (QALYs) gained by introducing PHiD-CV compared with PCV13 in routine vaccination. Our results indicated that PHiD-CV is cost-effective compared with PCV13 in Sweden. (Clin Ther. 2012;34:177-189) (C) 2012 Elsevier HS Journals, Inc. All rights reserved.
Original languageEnglish
Pages (from-to)177-189
JournalClinical Therapeutics
Volume34
Issue number1
DOIs
Publication statusPublished - 2012

Subject classification (UKÄ)

  • Pharmaceutical Sciences

Free keywords

  • cost-effectiveness analysis
  • costs
  • health outcomes
  • PHiD-CV
  • PCV13
  • pneumococcal disease
  • vaccine

Fingerprint

Dive into the research topics of 'Comparing Health Outcomes and Costs of General Vaccination with Pneumococcal Conjugate Vaccines in Sweden: A Markov Model'. Together they form a unique fingerprint.

Cite this